SLC5A2 and kidney disorder: First, the LGH registry data were retrospective and the treatment of patients in this time period did not reflect the latest draft 2024 KDIGO (Kidney Disease: Improving Global Outcomes) guidelines, which include the use of sodium-glucose cotransporter-2 inhibitors and dual endothelin angiotensin receptor antagonists [32].